Can a 14-Day Anti-Inflammatory shot stop heart failure after a heart attack?

NCT ID NCT05177822

Ongoing Disease control Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a drug called anakinra, which reduces inflammation, can help prevent heart failure in people who have just had a heart attack. About 84 participants will receive daily injections of anakinra or a placebo for up to 14 days. The goal is to see if blocking inflammation improves heart function and exercise capacity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anakinra (Kineret), an anti-inflammatory drug
What this could lead to: If it works, this could point toward a new way to prevent heart failure after a heart attack by calming inflammation.
What could go wrong: This is a small, early-phase trial with only 84 participants, so results may not apply to everyone. The drug is given for just 14 days, and its long-term benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction heart failure prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

University of Virginia

Charlottesville, Virginia, 22908, United States
Virginia Commonwealth University

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.